Measurement of plasma very long chain fatty acids is widely recognised as a sensitive screening test for X-linked adrenoleukodystrophy (X-ALD). This test has particular importance because of the highly variable clinical expression of X-ALD. In this affected family the progressive childhood form of X-ALD was accompanied by "non-diagnostic" concentrations of plasma very long chain fatty acids. The implications for diagnosis of X-ALD are discussed. (J Neurol Neurosurg Psychiatry 1994;57:759-761) 
This enabled the characteristic pathology3 and associated biochemical abnormality in the metabolism of very long chain fatty acids 4 to be identified. Since the description by Moser et al5 of an increased content of very long chain fatty acids (VLCFAs) in plasma, this assay has been widely used as a screening test for X-ALD and has aided in the identification of presymptomatic and asymptomatic cases as well as several different phenotypes of X-ALD6 (see table 1) . It is also recognised that women heterozygous for X-ALD may develop a spastic paraparesis .7 This is a report of one family with progressive childhood X-ALD in which the characteristic abnormalities of plasma VLCFAs were non-diagnostic and were regarded as normal. The implications for diagnostic evaluation of X-ALD families are discussed.
Case report HISTORY AND EXAMINATION
The proband was referred at the age of eight years with a history of longstanding learning difficulties with recent deterioration. There were no neonatal problems but cognitive development was slow from the beginning. He was walking without assistance by the age of one year but was slow to develop imaginative play, dressing and feeding skills, and speech. He attended a school for children with severe learning difficulties. For one year before referral he had seemed to have severe but variable visual impairment. He was becoming increasingly short tempered and withdrawn. He became unable to complete jigsaw puzzles and his handwriting deteriorated. He continued to enjoy a completely normal diet. In the family history, the patient had a maternal uncle who had died at the age of seven, one year after the onset of an unexplained neurological illness. His maternal grandmother had three siblings, all boys, of whom two had died in childhood.
On examination, the patient was quiet and withdrawn and had difficulty in understanding simple instructions. There was no abnormal skin pigmentation. He could visually fix on a face but was unable to point to a hand held in front of his eyes. Pupillary reactions to light were sluggish and the optic discs were pale. Tone and power in the limbs was normal. Deep tendon reflexes were brisk with spread of the biceps jerk to the fingers. Plantar response testing led to brisk withdrawal. There was no ataxia of the trunk or extremities.
INVESTIGATIONS
CT showed non-enhancing low attenuation in the white matter adjacent to the posterior horns of the lateral ventricles. A working clinical diagnosis of X-ALD was made because of the personal and family history, and findings on neurological examination and CT. Results of measurement of plasma VLCFA concentrations are reported later. Serum cortisol was 187 nmol/l before and 384 nmol/l 30 minutes after synacthen injection, which was interpreted as a normal response. White cell enzyme concentrations in blood and oligosaccharide concentrations in urine were normal. An electroretinogram was of normal amplitude and latency. Visually evoked potentials were delayed with latencies of 133 ms from each eye. 
Discussion
The diagnosis of X-ALD in this family seems certain yet plasma VLCFA concentrations were atypical with most or all variables in the We suggest that the diagnostic failure in this case resulted from insufficient recognition of the degree of overlap that exists between plasma VLCFA concentrations in ALD hemizygotes on the one hand and unaffected patients on the other. Results for plasma VLCFA in X-ALD should be divided into three categories: "typical of ALD", "normal" and "in need of further study". The delineation of this third category has been hindered by the diversity of reference ranges and their method of application by different laboratories.
In patients either with clinical abnormalities suggesting the diagnosis (including adrenomyeloneuropathy or presenile dementia), or at increased risk because of a positive family history, the possibility of X-ALD must be considered when plasma VLCFA concentrations are borderline, suggesting the need for further study. We suggest that such "borderline" results should include values at or above two SDs above controls in any one of the three values measured-namely, C26:0, C24/22, or C26/22. With such a criterion, all three laboratories would have classified our case as "in need of further study". Advice based on plasma VLCFA concentrations that can be classified as "normal" should be secure but even in this case, consideration should still be given to skin biopsy for VLCFA measurement in cultured fibroblasts if clinical suspicion of X-ALD is strong. 
